Leading a new front against cancer
We improve patient lives by unlocking the tissue phenome
In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer-relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies. Our vision is to create unique patient profiles for an individualized standard of care, where patients experience fewer side effects and live longer.
We offer a powerful quantification system to transform tissue image data into insights, paired with unique data-mining methods that open new opportunities for biomarker discovery.
Our work is the essential link to integrate all ‘omics data with clinical outcomes. We bridge molecular events and phenotypic effects to create validated tissue signatures that match patients and therapies.
Rely on us.
From the seed of an idea to its launch as a product, we support every step with meaningful knowledge and powerful tools that advance drug or diagnostic development and their transfer to the clinic.
How we partner
Our work model builds on a simple premise: Tissue Phenomics strengthens results, from biomarker discovery to clinical development and meaningful diagnostics. We bring Tissue Phenomics to you, seamlessly integrate into your processes, and act as your reliable, science-driven partner along the way.
Taking a ground-breaking technology that dramatically improves the information that can be extracted from histological images, Nobel Laureate Dr. Gerd Binnig founded Definiens in 1994. The goal? To create new opportunities for discovery and advances in oncology and immuno-oncology. Since then, Definiens technology has been used in thousands of projects, yielding results that have accelerated drug development and produced over 650 peer-reviewed publications. In 2013, Frost and Sullivan recognized Definiens as Company of the Year for Global Tissue Diagnostics and Pathology Imaging.
Definiens is now an international company with over 100 employees worldwide, and headquartered in Munich, Germany and Cambridge, USA.
A thought leader and technology innovator, Definiens brings the power of Tissue Phenomics to developments in oncology and immuno-oncology to improve patient, disease and treatment outcomes.
Read about the latest advancements and thought leading news from Definiens.
In the News
Join one of our Online Webinars, visit our booth at an upcoming Industry Event, or participate in our annual International Symposium. Learn how Definiens can help you.
Executive Management Team
Chief Executive Officer
Mr. Heydler was President and CEO at Barcelona Design Inc. based in San Jose, USA. Before joining Barcelona, Mr. Heydler served as President and CEO for InterPro Business Solutions, Inc., USA. He was Vice President and Executive Officer at Documentum Inc., a leading software and solutions provider with specific focus on the pharmaceutical and life sciences industry.
He built and drove Documentum’s European operations and assumed worldwide responsibility for Marketing and Documentum’s Application Business subsequently. Prior to this engagement, he served as Vice President and General Manager Europe for Cadence Design Systems and held senior leadership positions at Siemens AG.
Mr. Heydler holds a Diplom-Ingenieur degree in Electric Engineering and Computer Science from the Technical University in Munich.
Chief Financial Officer
Markus Rinecker, MD
Prior to joining Definiens, Dr. Rinecker served as Managing Director at one of the leading surgical hospitals in Munich. While managing 350 employees with full P&L responsibility, he established a new department for open heart surgery and streamlined organizational processes to increase the organization’s profitabiligy. For the hospital chain Humaine Kliniken GmbH he evaluated potential acquisition targets and participated in multiple share deal transactions. He was also actively involved in the start-up venture ProHealth AG, which opened Europe’s first full clinical proton radiation center for cancer therapy, in March 2009.
Dr. Rinecker holds a Doctoral Degree in Medicine at the Ludwig-Maximilians-University in Munich as well as a Masters Degree in Business Administration of INSEAD, France and Singapore.
Chief Medical Officer
Ralf Huss, MD
Prior to joining Definiens, Dr. Huss served as Global Head of Histopathology and Tissue Biomarkers at Roche Diagnostics, where he was involved in identifying new tissue biomarkers to stratify cancer patients as part of a global Personalized Healthcare strategy. Dr. Huss also co-founded the biotech company APCETH. He has training and experience in immunology, transplantation biology and stem cell research, has published more than 100 papers, and has worked with the Nobel Laureates Rolf Zinkernagel and E. Donnell Thomas.
In his role as Chief Medical Officer, Dr. Huss plays a key role in expanding Definiens’ image and data analysis into Tissue Diagnostics and Clinical Digital Pathology.
Dr. Huss holds global academic appointments at the Ludwig-Maximilians-University, Munich and the Wake Forest Institute for Regenerative Medicine, USA. He is also a Professor of Systems Biology at the University College Dublin.
Chief Commercial Officer
He joined Definiens from AYOXXA Biosystems where he was Corporate Vice President of Global Commercial Operations. Prior to that he was Corporate Vice President of Global Marketing and Business Development for Dako (now Agilent Technologies). During his career he has held leadership positions with Roche and Bayer Diagnostics in Europe, the US, and Latin America across 9 different countries. Michael Rasche is excellent at building and mobilizing high-performing international teams who view it as their mission to deliver business critical projects. In his role as Chief Commercial Officer, Mr. Rasche is responsible for continuing the momentum of Definiens driving sales in the strategic expansion from Research into the Clinical Development and Diagnostics Space.